FY 1995 Financial Report
You can read this report in its original form here. Total Income for FY 94-95 was $107,184. Total Expenses for FY 94-95 were $133,153. See original report.
Human Psychopharmacology of Psilocybin
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
FDA-Regulated Research and the Effort to Begin It
Dr. Donald Abrams’ FDA-approved research protocol, (IND#43,542) comparing the effectiveness of smoked marijuana and the oral THC capsule in promoting weight gain in patients suffering from the AIDS …
FY 1994 Financial Report
You can read this report in its original form here. Total Income for FY 93-94 was $106,650.48. There you have it, MAPS' financial report for FY 93-94. MAPS continues to grow as does its research agenda, …
Medical Marijuana Clinical Plan
A comprehensive clinical plan developed by MAPS in consultation with the FDA for the investigation of marijuana’s medical use in the treatment of the HIV-related wasting syndrome. This Clinical Plan …
FY 1993 Financial Report
At the beginning of this fiscal year, MAPS had about 350 members and $897 in the bank. By the end of the fiscal year, MAPS' membership had doubled to 707 and its balance was $46,066 (consisting of …
FY 1992 Financial Report
You can read this report in its original form here. MAPS' total income in FY 91-92 was $28,859.55. The following categories had no expenditures this fiscal year. Public Relations/Ads, Salaries, Grants, …
Doblin/Kleiman Survey of Oncologists
Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of oncologists’ experiences and attitudes. J Clin Oncol 1991 Jul;9(7):1314-9. 2002 New York Times Mention of Survey Reed Irvine, …
Documents from the DEA Scheduling Hearing of MDMA, 1984-1988
1.Introduction to the Legal Record of the DEA’s 1984-1988 MDMA Scheduling Hearings DEA Announcement of proposed scheduling of MDMA as a Schedule I Drug, Federal Register, July 27, 1984 2. Before …
LSD-Assisted Therapy
MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. LSD (lysergic acid diethylamide) is a semi-synthetic compound first …
MDMA-Assisted Therapy Study Protocols
Phase 3 Trials: FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD, Agrees on Special Protocol Assessment MAPS’ highest priority project is sponsoring Food and Drug Administration …
Other Psychedelic Research
See below for information about psychedelic research around the world not sponsored by MAPS. The studies listed here are limited to those in which psychedelics are administered to human subjects. Studies …